Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention (Q56944701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

5

G Montalescot

1 reference

8 November 2019

3

G W Stone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

2

R M Califf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

K M Anderson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

F J Neumann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

D P Miller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J J Ferguson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J T Willerson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H F Weisman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

language of work or name

English

0 references

publication date

1 June 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

2059-2065

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

Myonecrosis after revascularization procedures

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

1 reference

7 January 2021

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during n

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901290-6

7 January 2021

10.1016/S0735-1097(01)01290-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11419888%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference